Search

Author/Creator Amellal, N

1. 470PSafety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC). (23rd October 2018)

Authors:
Calvo Ferrandiz, A; Dahan, L; Hollebecque, A; Prager, G; Andre, T; Argiles Martinez, G; Bordonaro, R; Stein, A; Tortora, G; Leger, C; Amellal, N; Tabernero, J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 542PDroplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer. (23rd October 2018)

Authors:
Van Cutsem, E; Lesniewski-Kmak, K; Saunders, M P; Wasan, H; Argiles, G; Borg, C; Creemers, G-J M; Fedyanin, M; Glynne-Jones, R; Pfeiffer, P; Punt, C J A; Stroyakovskiy, D; Ten Tije, A J; van de Wouw, A; Cattan, V; Desachy, G; Amellal, N; Moiseyenko, V M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. O-022Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. (20th June 2018)

Authors:
Lesniewski-Kmak, K; Moiseenko, V; Saunders, M; Wasan, H; Argiles, G; Borg, C; Creemers, G; Fedyanin, M; Glynne-Jones, R; Pfeiffer, P; Punt, C; Stroyakovskiy, D; Ten Tije, A; Van de Wouw, A; Kanehisa, A; Fougeray, R; Busto, N Lopez; Amellal, N; Van Cutsem, E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. O-022Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. (20th June 2018)

Authors:
Lesniewski-Kmak, K; Moiseenko, V; Saunders, M; Wasan, H; Argiles, G; Borg, C; Creemers, G; Fedyanin, M; Glynne-Jones, R; Pfeiffer, P; Punt, C; Stroyakovskiy, D; Ten Tije, A; Van de Wouw, A; Kanehisa, A; Fougeray, R; Busto, N Lopez; Amellal, N; Van Cutsem, E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P-058Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis. (2nd July 2019)

Authors:
Fedyanin, M; Chekini, D; Chubenko, V; Tjulandin, S; Zhabina, A; Amellal, N; Aubel, P; Gandossi, E; Moiseenko, V
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search